Compare Stocks: MOLN, AVTE, AUTL, and VSTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.44 +4.3%	$1.74	$1.17 ▼ $2.58	$649.43M	2.07	1.82 million shs	1.51 million shs
AVTE Aerovate Therapeutics	$21.33 0.0%	$20.94	$89.95 ▼ $99.05	$618.25M	0.95	53,591 shs	595,723 shs
MOLN Molecular Partners	$4.29 -2.5%	$4.03	$3.53 ▼ $5.36	$173.17M	1.08	4,843 shs	2,111 shs
VSTM Verastem	$7.08 +3.2%	$5.54	$3.43 ▼ $11.24	$641.19M	0.26	2.22 million shs	1.19 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-2.90%	+2.63%	+61.38%	+39.29%	+33.71%
AVTE Aerovate Therapeutics	0.00%	-13.64%	+6.27%	-3.92%	+159.30%
MOLN Molecular Partners	0.00%	+2.92%	+11.96%	+8.64%	+17.02%
VSTM Verastem	-0.44%	-4.46%	+13.39%	+57.34%	-24.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.44 +4.3%	$1.74	$1.17 ▼ $2.58	$649.43M	2.07	1.82 million shs	1.51 million shs
AVTE Aerovate Therapeutics	$21.33 0.0%	$20.94	$89.95 ▼ $99.05	$618.25M	0.95	53,591 shs	595,723 shs
MOLN Molecular Partners	$4.29 -2.5%	$4.03	$3.53 ▼ $5.36	$173.17M	1.08	4,843 shs	2,111 shs
VSTM Verastem	$7.08 +3.2%	$5.54	$3.43 ▼ $11.24	$641.19M	0.26	2.22 million shs	1.19 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-2.90%	+2.63%	+61.38%	+39.29%	+33.71%
AVTE Aerovate Therapeutics	0.00%	-13.64%	+6.27%	-3.92%	+159.30%
MOLN Molecular Partners	0.00%	+2.92%	+11.96%	+8.64%	+17.02%
VSTM Verastem	-0.44%	-4.46%	+13.39%	+57.34%	-24.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.88	Moderate Buy	$10.00	309.84% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
MOLN Molecular Partners	2.25	Hold	$8.38	95.27% Upside
VSTM Verastem	2.80	Moderate Buy	$13.83	95.39% Upside

Current Analyst Ratings Breakdown

Latest MOLN, AVTE, AUTL, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$14.00 ➝ $13.00
8/7/2026	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$14.00 ➝ $12.00
8/3/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/31/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	MOLN Molecular Partners	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$15.00 ➝ $14.00
7/6/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	MOLN Molecular Partners	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/2/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
6/24/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$15.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$75.39M	8.61	N/A	N/A	$0.67 per share	3.64
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	$2.40 per share	N/A
VSTM Verastem	$87.53M	7.33	N/A	N/A	$0.74 per share	9.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
MOLN Molecular Partners	-$74.41M	-$1.94	N/A	N/A	N/A	N/A	-66.62%	-54.85%	8/25/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest MOLN, AVTE, AUTL, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/24/2026	Q2 2026	MOLN Molecular Partners	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	1.04	4.89	4.40
AVTE Aerovate Therapeutics	N/A	8.78	8.78
MOLN Molecular Partners	N/A	9.43	9.43
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
AVTE Aerovate Therapeutics	N/A
MOLN Molecular Partners	26.55%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
AVTE Aerovate Therapeutics	24.90%
MOLN Molecular Partners	5.93%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.16 million	197.76 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
VSTM Verastem	50	90.56 million	88.81 million	Optionable

MOLN, AVTE, AUTL, and VSTM Headlines

Recent News About These Companies

Verastem (NASDAQ:VSTM) Shares Down 8.6% - Should You Sell?

August 20, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Shares Up 6.4% - What's Next?

August 17, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Downgraded to "Sell" Rating by Wall Street Zen

August 15, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

Verastem (VSTM) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM

August 12, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS

August 7, 2026 | marketbeat.com

Verastem Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings

August 7, 2026 | marketbeat.com

Verastem Restructures Oberland Financing to Support Commercialization

August 7, 2026 | tipranks.com

Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained

August 7, 2026 | tipranks.com

Verastem: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

August 6, 2026 | finance.yahoo.com

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Moderate Buy" by Brokerages

August 2, 2026 | marketbeat.com

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

July 30, 2026 | tipranks.com

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic ...

July 30, 2026 | finance.yahoo.com

Verastem Oncology (NASDAQ:VSTM) Draws Fresh Market Focus

July 30, 2026 | kalkinemedia.comK

Verastem (VSTM) to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, AVTE, AUTL, and VSTM Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.44 +0.10 (+4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 -0.02 (-0.61%)

As of 04:23 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Aerovate Therapeutics NASDAQ:AVTE

$21.33 -0.01 (-0.05%)

As of 08/24/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Molecular Partners NASDAQ:MOLN

$4.29 -0.11 (-2.52%)

Closing price 03:58 PM Eastern

Extended Trading

$4.24 -0.05 (-1.26%)

As of 04:10 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Verastem NASDAQ:VSTM

$7.08 +0.22 (+3.21%)

Closing price 04:00 PM Eastern

Extended Trading

$7.08 +0.00 (+0.07%)

As of 04:10 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, AVTE, AUTL, and VSTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, AVTE, AUTL, and VSTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, AVTE, AUTL, and VSTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, AVTE, AUTL, and VSTM Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Aerovate Therapeutics NASDAQ:AVTE

Molecular Partners NASDAQ:MOLN

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, AVTE, AUTL, and VSTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, AVTE, AUTL, and VSTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, AVTE, AUTL, and VSTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, AVTE, AUTL, and VSTM Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Aerovate Therapeutics NASDAQ:AVTE

Molecular Partners NASDAQ:MOLN

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools